Analyser av Physitrack

Physitrack (Q1 Interview): Growth pivot starts here; RTM to lead the US offensive - Redeye

Following the release of the Q1 2026 report, Physitrack's CEO, Henrik Molin, joins us to discuss the group's transition from structural clea...

Redeye • I förrgår 07:30

Physitrack (Q1 Review): Enters a new growth phase - Redeye

Physitrack’s Q1 2026 report confirms that the structural "SaaS-only" reset has successfully protected the bottom line, with the Group demons...

Redeye • I förrgår 07:24

Physitrack (Q1 Initial take): Results close to expectations; RTM and US listing in focus - Redeye

Physitrack’s Q1 2026 report landed close to our overall expectations, maintaining the stable and profitable trajectory the Group has maintai...

Redeye • 23 apr 08:58

Physitrack (Q1 Preview): Focus on margin resilience and growth inflection - Redeye

Redeye shares its preview of Physitrack’s Q1 results, due on 23 April.

Redeye • 08 apr 08:25

Physitrack: Strengthening Swiss presence with Lifecare wins - Redeye

Physitrack has announced two new agreements in Switzerland within its Lifecare division, signaling a regained momentum in the segment after ...

Redeye • 27 mar 10:13

Physitrack (Q4 Review): Strategic reset complete; pivot to pure-SaaS growth acceleration - Redeye

Redeye has updated its estimates and valuation following Physitrack’s Q4 2025 report.

Redeye • 03 mar 07:29

Physitrack (Q4 Initial take): In line with preliminary results - Redeye

Physitracks Q4 results aligned with its preliminary figures, highlighted by continued margin expansion and improved free cash flow (FCF) for...

Redeye • 27 feb 08:52

Physitrack: Initiating Buyback program - Redeye

Physitrack’s board has announced its intention to implement a share buyback program (SBB) for up to 10% of the issued capital.

Redeye • 20 feb 10:11

Physitrack (Q4 preliminary figures): Margins improving, but growth stalled - Redeye

Physitrack released preliminary Q4 2025 figures this morning, which were broadly in line with our expectations.

Redeye • 29 jan 09:17

Physitrack (Q4 Preview): Profitability strength amidst muted growth - Redeye

Redeye shares its view on Physitrack ahead of the preliminary trading update scheduled for 29 January, followed by the Q4 and Annual Report ...

Redeye • 19 jan 07:22

Physitrack: Wellness exit sharpens focus on high-margin SaaS - Redeye

Redeye comments on the recently announced continuing restructuring of the Wellness division, which represents the final step in the company’...

Redeye • 26 nov 2025 07:23

Physitrack (Q3 Review): Staying on track with solid profitability and cash flow - Redeye

Redeye has updated its estimates following Physitrack’s Q3 2025 report, which was broadly in line with expectations.

Redeye • 22 okt 2025 07:16

Physitrack (Q3 Initital take): Stable quarter with continued margin expansion and solid cash flow - Redeye

Redeye sees a Q3 report from Physitrack largely in line with our expectations.

Redeye • 21 okt 2025 09:13

Physitrack Q3 Preview: Profitability momentum continues despite Wellness softness - Redeye

Redeye comments on Physitrack ahead of its Q3 results, due on 21 October (rescheduled from 31 October).

Redeye • 06 okt 2025 07:10

Physitrack: Large block transaction – removal of share overhang - Redeye

Redeye views last Friday’s large block transaction in Physitrack shares as a clear positive for the stock.

Redeye • 26 aug 2025 08:43

Physitrack: Turning point for profitability - Redeye

Physitrack delivered a solid Q2, highlighted by margin expansion, positive free cash flow, and greater operational efficiency.

Redeye • 28 jul 2025 08:04

Physitrack Q2 2025: Continued margin expansion and cash flow uplift - Redeye

Physitrack’s Q2 2025 results came in broadly in line with our expectations.

Redeye • 24 jul 2025 09:14

Physitrack: Q2 2025e Preview – Leaner cost base boosts margins and cash flow - Redeye

Redeye comments on Physitrack ahead of its Q2 results, due on 18 July (rescheduled from 31 July).

Redeye • 15 jul 2025 08:28

Physitrack: Solid start to 2025 with improving margins - Redeye

Physitrack’s Q1 2025 report marked a solid start to the year, with sales broadly in line and profitability supported by continued cost effic...

Redeye • 06 maj 2025 07:21

Physitrack Q1 2025: In line with expectations - Redeye

Redeye shares its initial take on Physitrack’s Q1 2025 results.

Redeye • 02 maj 2025 09:54

Physitrack Q1 2025 Preview: Early indications of enhanced profitability anticipated - Redeye

We expect Physitrack’s ongoing streamlining and consolidation efforts to begin bearing fruit in Q1 2025.

Redeye • 15 apr 2025 07:24

Physitrack: Divestment of Wellnow - Redeye

Redeye comments on Physitrack’s announcement regarding the divestment of its German wellness subsidiary, Wellnow.

Redeye • 01 apr 2025 07:27

Physitrack: Strong Finish to the Year, well positioned for 2025 - Redeye

Physitrack’s Q4 2024 report came in stronger on sales than expected but slightly below profitability due to a higher-than-anticipated cost b...

Redeye • 03 mar 2025 07:24

Physitrack Q4 2024: Topline beat - Redeye

Redeye shares its initial take on Physitrack’s Q4 results, which came in above our expectations in terms of the top line.

Redeye • 28 feb 2025 09:51

Physitrack: Preview Q4 2024e and recent contract wins (EUR1.7m) - Redeye

Redeye expects strong performance from the Lifecare division in Q4 2024, though weaker results from the Wellness division will likely constr...

Redeye • 17 feb 2025 10:52

Physitrack: Cost savings and streamlining of Champion Health - Redeye

Redeye briefly comments on Physitrack’s announcement to streamline its subsidiary, Champion Health, and the settlement of the share purchase...

Redeye • 14 jan 2025 07:22

Physitrack: Strategic restructure of Champion Health Plus - Redeye

Redeye is encouraged by the announcement of a strategic restructuring of Champion Health Plus.

Redeye • 06 dec 2024 07:24

Physitrack Q3 2024: Soft short-term outlook - Redeye

Redeye has updated its estimates and valuation following Physitrack’s Q3 report.

Redeye • 13 nov 2024 07:28

Physitrack Q3 2024: A modest quarter, in line with expectations - Redeye

Redeye shares its initial take on Physitrack’s Q3 results, which were generally in line with our modest expectations.

Redeye • 12 nov 2024 09:02

Physitrack: Preview Q3 2024e - Redeye

Redeye anticipates the Lifecare division to maintain its solid performance in Q3 2024, though weaker results from the Wellness division will...

Redeye • 23 okt 2024 10:17

Physitrack: Short-term challenges - Redeye

Redeye provides updated estimates and valuation following Physitrack’s Q2 report.

Redeye • 14 aug 2024 08:09

Physitrack Q2 2024: In line – Wellness holds back overall growth - Redeye

Redeye leaves its initial take on Physitrack’s Q2 figures, which overall was line with our expectations.

Redeye • 13 aug 2024 09:29

Physitrack: Preview Q2 2024e - Redeye

Redeye anticipates a muted Q2 2024 in terms of quarter-on-quarter growth, though stable ARR growth is expected both year-on-year and quarter...

Redeye • 29 jul 2024 08:32

Physitrack: Steady beginning to 2024 - Redeye

Redeye reiterates its positive stance following Physitrack’s Q1 results.

Redeye • 15 maj 2024 08:14

Physitrack Q1 2024: Strong ARR growth - Redeye

Redeye comments on Physitrack’s soild Q1 figures, which were in line with our expectations.

Redeye • 14 maj 2024 08:53

Physitrack preview Q1 2024: Back to q/q growth - Redeye

Redeye anticipates that Physitrack will resume its sequential growth trajectory in Q1 2024, albeit with slightly muted year-on-year growth, ...

Redeye • 22 apr 2024 09:05

Physitrack: Prioritising positive cash flow holds back topline growth - Redeye

Redeye has updated our estimates and fair value range in response to Physitrack’s Q4 2023 report, which slightly missed our topline expectat...

Redeye • 01 mar 2024 07:27

Physitrack Q4 2024: Softer topline but positive FCF - Redeye

Redeye comments on Physitrack’s Q4 figures, which slightly missed our expectations on topline.

Redeye • 28 feb 2024 14:45

Physitrack preview Q4 2023: Strong cash generation expected - Redeye

Redeye anticipates that Physitrack’s Q4 2023 results will demonstrate robust cash generation, organic growth of 15% y/y, and sequentially su...

Redeye • 12 feb 2024 09:03

Physitrack: Champion Health Nordic’s Largest Contract – SEK4m Revenue Expected in 2024 - Redeye

Redeye is encouraged to discover that Champion Health Nordic (a subsidiary within the Wellness division) has secured its most significant co...

Redeye • 28 nov 2023 08:49

Physitrack Q3 2023: Tracking profitable growth - Redeye

Redeye has revised our estimates and fair value range following Physitrack’s Q3 2023 report, which came in close to our forecasts.

Redeye • 15 nov 2023 08:22

Physitrack: In line with expectations - Redeye

Redeye concludes that the figures in Physitrack’s Q3 2023 report were generally in line with our estimates.

Redeye • 14 nov 2023 09:01

Physitrack Q3 2023: Preview - Redeye

Physitrack will release its Q3 2023 report on 14 November at 08:00 and host a conference call at 10:00.

Redeye • 06 nov 2023 09:09

Redeye SaaS Update Q2 2023: Valuations Dropping Further - Redeye

Redeye provides its Q2 2023 sector update for the Nordic SaaS space.

Redeye • 11 sep 2023 10:35

Physitrack: Steady state - Redeye

Redeye updates its estimates and fair value range after Physitrack’s stable Q2 2023 report, which came in close to our forecasts.

Redeye • 16 aug 2023 09:19

Physitrack Q2 2023: Initial take - Redeye

Redeye comments on Physitracks’s Q2-results, wherein the reported figures generally align with our estimates.

Redeye • 15 aug 2023 08:59

Physitrack: Preview Q2’23 - Redeye

Redeye provides an update on Physitrack ahead of its Q2’23-results (scheduled for 18 August), anticipating a steady quarter marked by favour...

Redeye • 07 aug 2023 08:12

Physitrack: Tracking growth with two business divisions priced as one - Redeye

Redeye initiates coverage on Physitrack, a scalable and rapidly growing e-health software company that assists corporations in improving emp...

Redeye • 16 maj 2023 07:22

Physitrack: Fortsatt hög efterfrågan och stabil marginal - Penser

Stark tillväxt tyder på fortsatt god efterfrågan Physitrack fortsätter att växa snabbt med en total tillväxt på 45% jämfört med föregående å...

Penser • 03 maj 2023 11:47

Physitrack: No trend changes - ABG

Strong PF growth but the margin was flat sequentially We lower '23e-'25e adj.

ABG Sundal Collier • 03 maj 2023 07:40

Physitrack: Stark tillväxt under det första kvartalet - Penser

Stark tillväxt, drivet av båda segmenten Physitrack rapporterade i morse en stark omsättningstillväxt som var något högre än vad vi förvänta...

Penser • 02 maj 2023 11:06

Physitrack: Strong LC growth, but small margin miss - ABG

Q1 sales in line with our estimates, adj. EBITDA 4% below Expect cons '23e adj.

ABG Sundal Collier • 02 maj 2023 09:31

Physitrack: Organic growth back >30%, but softer margin - ABG

Q1e 36% org. growth, but limited margin improvement q-o-q We cut '23e-'24e adj.

ABG Sundal Collier • 21 apr 2023 08:37

Physitrack: Vändning i sikte - Penser

Rekryterar för att fortsätta utveckla erbjudandet och bibehålla tillväxttakten 2022 var ett händelserikt år för Physitrack där mycket fokus ...

Penser • 14 apr 2023 11:15

Physitrack: Högre marginaler att vänta under 2023 - Penser

Förväntat lägre marginal under sista kvartalet Kvartalet var i stort sett som vi förväntat oss med en total tillväxt på 38% y/y och proforma...

Penser • 02 mar 2023 11:34

Physitrack: Cash flow turnaround in '23? - ABG

Share down 20% today despite limited changes to outlook We expect positive FCF ex.

ABG Sundal Collier • 01 mar 2023 07:49

Physitrack: Q4 largely in line with our expectations - ABG

Q4 was in line versus our sales and adj. EBITDA estimates Slight cons miss but reassuring '23 margin outlook Share is -14% YTD, trading at 1...

ABG Sundal Collier • 28 feb 2023 09:01

Physitrack: Growth continues, but slight margin pressure - ABG

Q4e to show strong growth but slightly weaker margin We trim '23e-'24e adj.

ABG Sundal Collier • 14 feb 2023 07:43

Physitrack: Visar styrka i orolig omvärld - Penser

Q3 i korthet Under det tredje kvartalet 2022 uppvisade Physitrack en omsättning om EUR 3,4m (EUR 2,0 Q3’21) vilket motsvarar en tillväxt om ...

Penser • 10 nov 2022 11:04

Physitrack: Fortsatt lönsam tillväxt - Penser

Fortsatt hög tillväxt Omsättningen under Q2’22 uppgick till EUR 3,1m (EUR 1,9m), vilket motsvarar en total tillväxt om 57% y/y och proforma ...

Penser • 30 aug 2022 12:38

Physitrack: Delivery on track - ABG

Pro forma growth in line with company target Margin slightly pressured by virtual care acquisitions Trading at 14 ‘23e EV/EBITDA Wellness ...

ABG Sundal Collier • 26 aug 2022 10:32

Physitrack Q2: 31% proforma growth - ABG

Q2: Limited deviations on sales and adj. EBITDA Small negative cons adj.

ABG Sundal Collier • 25 aug 2022 09:32

Physitrack: Continuing to develop the Wellness offering - ABG

One add-on and an important partnership in Q2 Small rise in subscription sales, while lowering care The share is trading at 6.

ABG Sundal Collier • 29 jul 2022 08:14

Physitrack: Stabil tillväxt, marginal och ytterligare ett förvärv - Penser

Tillväxt om 67% i Q1'22 Omsättningen i Q1'22 uppgick till EUR 2,6m (EUR 1,5m i Q1’21), vilket motsvarar en tillväxt om 67% y/y.

Penser • 27 maj 2022 11:02

Physitrack: Set to continue growing subscription sales - ABG

New initiatives to grow subscription sales in the pipeline Seasonality changes and adding new revenue stream Share trading at 15.

ABG Sundal Collier • 27 maj 2022 10:49

Physitrack: Continues to increase the subscriber base - ABG

Q1 sales of EUR 2.6m (-5.7% vs ABGSC) The number of subscribers +17% y-o-y (vs ABGSC 21%) Expect relatively small forecasts changes Q1 resu...

ABG Sundal Collier • 25 maj 2022 10:13

Physitrack: All set for strong growth to continue - ABG

Physitrack stays strong despite external disruptions We add Champion Health to the figures Share trades more than 40% below Nordic SaaS pee...

ABG Sundal Collier • 10 maj 2022 15:09

Physitrack: Enhances its holistic care offering - ABG

Acquires a leading digital workplace health platform Adding (at least) 3.

ABG Sundal Collier • 09 maj 2022 08:41

Physitrack: Nytt värdeskapande förvärv - Penser

Ny rapportering Physitrack går från brutet räkenskapsår till kalenderår.

Penser • 25 feb 2022 11:04

Physitrack: Starkt avslut på 2021 - Penser

God tillväxt Physitrack redovisade en omsättning om 2,4m EUR (0,9m) under Q4'21, vilket motsvarar en tillväxt om 165% y/y.

Penser • 27 jan 2022 11:08